Successes and gaps in the HIV cascade of care of a high HIV prevalence setting in Zimbabwe: a population-based survey.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
09 2020
Historique:
received: 05 03 2020
revised: 20 06 2020
accepted: 31 07 2020
entrez: 24 9 2020
pubmed: 25 9 2020
medline: 11 5 2021
Statut: ppublish

Résumé

Gutu, a rural district in Zimbabwe, has been implementing comprehensive HIV care with the support of Médecins Sans Frontières (MSF) since 2011, decentralizing testing and treatment services to all rural healthcare facilities. We evaluated HIV prevalence, incidence and the cascade of care, in Gutu District five years after MSF began its activities. A cross-sectional study was implemented between September and December 2016. Using multistage cluster sampling, individuals aged ≥15 years living in the selected households were eligible. Individuals who agreed to participate were interviewed and tested for HIV at home. All participants who tested HIV-positive had their HIV-RNA viral load (VL) measured, regardless of their antiretroviral therapy (ART) status, and those not on ART with HIV-RNA VL ≥ 1000 copies/mL had Limiting-Antigen-Avidity EIA Assay for cross-sectional estimation of population-level HIV incidence. Among 5439 eligible adults ≥15 years old, 89.0% of adults were included in the study and accepted an HIV test. The overall prevalence was 13.6% (95%: Confidence Interval (CI): 12.6 to 14.5). Overall HIV-positive status awareness was 87.4% (95% CI: 84.7 to 89.8), linkage to care 85.5% (95% CI: 82.5 to 88.0) and participants in care 83.8% (95% CI: 80.7 to 86.4). ART coverage among HIV-positive participants was 83.0% (95% CI: 80.0 to 85.7). Overall, 71.6% (95% CI 68.0 to 75.0) of HIV-infected participants had a HIV-RNA VL < 1000 copies/mL. Women achieved higher outcomes than men in the five stages of the cascade of care. Viral Load Suppression (VLS) among participants on ART was 83.2% (95% CI: 79.7 to 86.2) and was not statistically different between women and men (p = 0.98). The overall HIV incidence was estimated at 0.35% (95% CI 0.00 to 0.70) equivalent to 35 new cases/10,000 person-years. Our study provides population-level evidence that achievement of HIV cascade of care coverage overall and among women is feasible in a context with broad access to services and implementation of a decentralized model of care. However, the VLS was relatively low even among participants on ART. Quality care remains the most critical gap in the cascade of care to further reduce mortality and HIV transmission.

Identifiants

pubmed: 32969602
doi: 10.1002/jia2.25613
pmc: PMC7513352
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25613

Informations de copyright

© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

PLoS One. 2012;7(3):e33328
pubmed: 22479384
J Int AIDS Soc. 2017 Jul 3;20(1):21419
pubmed: 28691437
Lancet. 1997 Feb 1;349(9048):352-3
pubmed: 9024392
J Int AIDS Soc. 2017 Mar 22;19(1):21345
pubmed: 28364560
N Engl J Med. 2017 Oct 26;377(17):1605-1607
pubmed: 29069566
AIDS. 2015 Jul 31;29(12):1557-65
pubmed: 26244395
Lancet. 2009 Oct 17;374(9698):1329
pubmed: 19837252
Epidemiology. 2012 Sep;23(5):721-8
pubmed: 22627902
PLoS One. 2013 Oct 15;8(10):e77101
pubmed: 24143205
PLoS Med. 2011 Oct;8(10):e1001102
pubmed: 21990966
BMC Public Health. 2018 Mar 2;18(1):303
pubmed: 29499668
PLoS Med. 2017 Apr 11;14(4):e1002262
pubmed: 28399122
AIDS Behav. 2013 Nov;17(9):2946-53
pubmed: 23142856
BMC Public Health. 2009 Jun 05;9:174
pubmed: 19500373
Lancet HIV. 2016 Apr;3(4):e152-4
pubmed: 27036988
J Acquir Immune Defic Syndr. 2014 May 1;66 Suppl 1:S13-26
pubmed: 24445338
Lancet Infect Dis. 2011 Jul;11(7):525-32
pubmed: 21546309
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
N Engl J Med. 2006 Feb 2;354(5):437-40
pubmed: 16452553
Lancet Infect Dis. 2013 May;13(5):459-64
pubmed: 23537801
J Int AIDS Soc. 2016 Feb 15;19(1):20673
pubmed: 26894388
PLoS One. 2015 Mar 31;10(3):e0122783
pubmed: 25826655
Curr HIV/AIDS Rep. 2009 Nov;6(4):217-23
pubmed: 19849965

Auteurs

Rebecca M Coulborn (RM)

Epicentre, Paris, France.

Erica Simons (E)

Epicentre, Paris, France.

Abraham Mapfumo (A)

Médecins Sans Frontières (MSF), Harare, Zimbabwe.

Tsitsi Apollo (T)

Ministry of Health and Child Care, Harare, Zimbabwe.

Daniela B Garone (DB)

Médecins Sans Frontières (MSF), Harare, Zimbabwe.

Esther C Casas (EC)

Southern Africa Medical Unit, MSF, Cape Town, South Africa.

Adrian J Puren (AJ)

National Institute for Communicable Diseases (NICD), National Health Laboratory Service, Johannesburg, South Africa.
Division of Virology, School of Pathology, University of the Witwatersrand Medical School, Johannesburg, South Africa.

Menard L Chihana (ML)

Epicentre, Paris, France.

David Maman (D)

Epicentre, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH